Adar Poonawalla commits 100 million doses of vaccines every year to Biocon Biologics

Biocon Biologics will offer 15% stake to Serum Institute Life Sciences

September 17, 2021 02:25 pm | Updated November 19, 2021 08:28 pm IST - Bengaluru

 

Biocon Biologics Limited (BBL) will offer approximately 15% stake to Serum Institute Life Sciences Private Limited (SILS) at a post-money valuation of $4.9 billion in exchange for committed access to 100 million doses of vaccines per annum for 15 years, primarily from SILS’s upcoming vaccine facility in Pune with commercialisation rights of the SILS vaccine portfolio, including COVID-19 vaccines, for global markets.

Biocon Biologics Limited (BBL) is a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS) is a subsidiary of Serum Institute of India.

Pursuant to the terms of the agreement, BBL would generate a committed revenue stream and related margins, commencing H2 of FY23.

Adar Poonawalla, CEO, Serum Institute of India, with Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics.

Adar Poonawalla, CEO, Serum Institute of India, with Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics.

 

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics, said, “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics.''

Adar Poonawalla, CEO, Serum Institute of India, said, “We look forward to complementing each other’s capabilities and capacities in vaccines and biologics with the objective of addressing inequitable access, both in emerging and developed markets, for life-saving vaccines and biologics.”

 

Mr. Poonawalla will get a seat on the board of Biocon Biologics Limited.

In addition to vaccines, the strategic alliance would develop antibodies targeting several infectious diseases like dengue and HIV.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.